Articles related to CHECKPOINT INHIBITORS

“Myeloid cells are among the first group of immune cells recruited to tumors, but very quickly these tumor-fighting cells turn into tumor-supporting cells.”

Patients receiving pembrolizumab before, during, and after surgery demonstrated longer event-free survival and higher substantial tumor shrinkage rates, with median survival extending from 30.4 to 51.8 months compared to standard care alone.

Reed-Sternberg cells harbor chromosome 9p24 amplification encoding PD-1 ligand, creating therapeutic vulnerability exploited by checkpoint inhibitors with remarkable clinical responses.

In mice whose immune cells that lack the ability to recognize flagellin, immune therapy induced long-term control of ovarian tumor growth in almost 80% of animals.

Pembrolizumab now represents a transformative advancement in the adjuvant treatment of clear cell renal cell carcinoma, significantly reducing the risk of progression or death by 38% compared to placebo.

The ESMO Congress 2023 has highlighted how international studies in NSCLC are currently being reported at a rapid pace. This underscores the importance of staying updated on these advancements to provide optimal patient care.